Sickle Cell Anemia Drug Gains FDA Approval

The FDA today granted regular approval to hydroxyurea (Siklos) to decrease the prevalence of painful crises and the need for transfusions in pediatric patients aged 2 years and older with sickle cell anemia with moderate-to-severe painful crises, according to a press release.
This was the first approval for hydroxyurea indicated for pediatric patients with sickle cell disease, the FDA said.
The approval was based on findings from the European Sickle Cell Disease Cohort study, which included 405 patients with sickle cell disease aged 2 to 18 years, of whom 141 were not previously-treated.  
The investigators found that treatment with hydroxyurea resulted in increased hemoglobin F levels, according to the release.
The prevalence of patients who experienced at least 1 vaso-occlusive episode, 1 episode of acute chest syndrome, 1 hospitalization, or 1 blood transfusion was reduced after 12 months of treatment, according to the FDA.
Common adverse reactions occurring in less than 10% of hydroxyurea-treated patients included infections and neutropenia.
The FDA previously granted hydroxyurea orphan drug designation, according to the release.
Earlier this year, the FDA approved L-glutamine oral powder (Endari) for the treatment of sickle cell disease in patients 5 years and older, making it the first drug approved in 20 years.
The approval of both therapies will likely make treatment accessible for many patients with sickle cell disease. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Tivozanib (Fotivda) improved progression-free survival and reduced risk of death in patients with highly refractory advanced or metastatic disease.
Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.